US/UK/Canada

Share

Pick a time period -
Tags ( Active)

DanCann Pharma A/S: No warrants exercised in extraordinary exercise period in connection with delisting

COPENHAGEN, Denmark, 13 January 2026 – DanCann Pharma A/S, CVR-no. 39426005 (SS: DANCAN), a Danish medicinal cannabis company listed on Spotlight Stock Market (“DanCann Pharma” or the “Company”) announced on 29 December 2025 that an extraordinary exercise period for a total of 1,224,993 warrants commenced as a result of the Company’s application for a delisting. The last day of the extraordinary exercise period was yesterday, and no warrants have been exercised.No exercise of warrants As announced on 29 December 2025, a total of 1,224,993 outstanding warrants in the Company issued

Spotlight Stock Market has approved DanCann Pharma A/S’ application for a voluntary delisting

COPENHAGEN, Denmark, 8 January 2026 – DanCann Pharma A/S, CVR-no. 39426005 (SS: DANCAN), a Danish medicinal cannabis company listed on Spotlight Stock Market (“DanCann Pharma” or the “Company”) has on 7 January 2026 submitted to Spotlight Stock Market an application for a voluntary delisting of its shares from Spotlight Stock Market. Today, Spotlight Stock Market has approved the Company’s application for a delisting, and consequently the Company’s shares will be delisted from Spotlight Stock Market.Delisting application approved On 7 January 2026, the board of directors of the Company

DanCann Pharma A/S has today applied for a voluntary delisting from Spotlight Stock Market

COPENHAGEN, Denmark, 7 January 2026 – DanCann Pharma A/S’, CVR-no. 39426005 (SS: DANCAN), a Danish medicinal cannabis company listed on Spotlight Stock Market (“DanCann Pharma” or the “Company”) general meeting approved on 21 October 2025 that DanCann Pharma shall apply for a voluntary delisting of its shares from Spotlight Stock Market, and the Company has today submitted to Spotlight Stock Market an application for a voluntary delisting of its shares from Spotlight Stock Market.Application for delisting On 6 October 2025, the Company announced that the Company has resolved to apply for

DanCann Pharma A/S: Chairman’s New Year Update

COPENHAGEN, Denmark, 6 January 2026 – DanCann Pharma A/S (CVR no. 39426005), a Danish medicinal cannabis company listed on Spotlight Stock Market under the ticker symbol SS: DANCAN (the “Company” or “DanCann Pharma”), today provides a New Year update from the Chairman of the Board of Directors, Carsten Trads, addressing recent strategic developments and the Company’s current position following the divestment of CannGros ApS and the forthcoming delisting.On behalf of the Board of Directors, I would like to provide a New Year update following the recent strategic developments, including the

DanCann Pharma A/S: Extraordinary exercise period for warrants commences today as a result application for delisting

COPENHAGEN, Denmark, 29 December 2025 – DanCann Pharma A/S’, CVR-no. 39426005 (SS: DANCAN), a Danish company listed on Spotlight Stock Market (“DanCann Pharma” or the “Company”) general meeting approved on 21 October 2025 that DanCann Pharma shall apply for a voluntary delisting of its shares from Spotlight Stock Market, and the application will be submitted to Spotlight Stock Market on 7 January 2026. For a total of 1,224,993 outstanding warrants in the Company, a delisting is deemed an “Exit” under the warrant terms which will entitle the warrant holders to exercise their warrants, and

DanCann Pharma A/S Completes Sale of CannGros ApS to StenoCare A/S through Equity Transaction

COPENHAGEN, Denmark, 17 November, 2025 – DanCann Pharma A/S, CVR-no. 39426005 (SS: DANCAN), a Danish company powered by cannabinoids listed on Spotlight Stock Market (“DanCann Pharma”), and StenoCare A/S, CVR-no. 39024705, a medical cannabis company listed on the Nasdaq First North Growth Market Denmark (“StenoCare”), announce that they have entered into a Share Purchase Agreement (the “Agreement” or the “SPA”). Under the Agreement, DanCann Pharma divests 100% of its shares in its wholly owned subsidiary, CannGros ApS, CVR-no. 39039451 (“CannGros”), to StenoCare, against issue of shares in

DanCann Pharma A/S delivers Q3 2025 Highlights – Leadership Transition, Strategic Progress, and Path Toward Delisting

COPENHAGEN, Denmark, 27 October 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, today announces its financial results and operational highlights for the third quarter (Q3) of 2025. The period was marked by continued operational progress, strategic transformation, and key organizational changes. The Q3-2025 report is available as an attached document to this press release and at www.dancann.com.Summary: Group key figures Q3 2025 DKK ‘000 01/07/25– 01/07/24– 01/01/25– 01/01/24– 2024 Full year 30/

Minutes of Extraordinary General Meeting held in DanCann Pharma A/S

Minutes of Extraordinary General Meeting held in DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”) On 21 October 2025 at 09:00 am (CET), an extraordinary general meeting was held in the Company at the Company’s address, Rugvænget 5, 6823 Ansager, Denmark. The agenda for the extraordinary general meeting was as follows: Proposal to approve the board of directors’ resolution of 6 October 2025 1. to apply for a voluntary delisting of the Company’s shares from Spotlight Stock Market and adopt amendments to the Company’s articles of association. (proposed by the

DanCann Pharma A/S: Chairman’s Letter to the Shareholders - CEO Transition and Voluntary Delisting

COPENHAGEN, Denmark, 06 October 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, today publishes a letter from the Chairman of the Board. The letter provides additional context and elaboration on the Company’s recent communications, outlining the current organizational developments, the voluntary delisting, and the strategic considerations guiding the Company’s next steps.Dear Shareholders, On behalf of the Board of Directors of DanCann Pharma, I write to you at a time of important organizational change and strategic

NOTICE OF EXTRAORDINARY GENERAL MEETING IN DANCANN PHARMA A/S

The Board of Directors hereby convenes an extraordinary general meeting of DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”), to be held on Tuesday, 21 October 2025 at 09:00 am (CET) at DanCann Pharma A/S’ address, Rugvænget 5, 6823 Ansager, Denmark The agenda for the extraordinary general meeting is as follows: Proposal to approve the board of directors’ resolution of 6 October 2025 1. to apply for a voluntary delisting of the Company’s shares from Spotlight Stock Market and adopt amendments to the Company’s articles of association. (proposed by the board

DanCann Pharma A/S has resolved to apply for delisting from Spotlight Stock Market, subject to approval by the general meeting

COPENHAGEN, Denmark, 6 October 2025 – The board of directors of DanCann Pharma A/S (publ.) (“DanCann Pharma” or the “Company”) has today resolved to apply for a voluntary delisting of the Company’s shares from Spotlight Stock Market. The resolution is conditional upon approval hereof by the general meeting of the Company. A notice convening an extraordinary general meeting will be published today by way of a separate press release.Background DanCann Pharma A/S was founded on 20 March 2018, and the Company’s shares were admitted to trading on Spotlight Stock Market on 12 November 2020.

DanCann Pharma A/S: Delivers Q2-2025 Highlights

COPENHAGEN, Denmark, 25 August 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the second quarter (Q2) of 2025. The Q2-2025 report is available as an attached document to this press release and at www.dancann.com.Summary: Group Key Figures Q2-2025  DKK 1,000 01/04/25 01/04/24 01/01/25 – 30/06/25 01/01/24 – 30/06/24 – 30/06/25 – 30/06/24 Net Sales 1,182 3,856 1,427 4,551EBITDA -2,236

DanCann Pharma A/S shares supplementary details of the obtained bridge loan

COPENHAGEN, Denmark, 9 July 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby provides additional information regarding the bridge loan facility previously announced (the “Loan”).Terms of the Loan The Company has entered into a bridge loan agreement in the amount of DKK 2 million with a syndicate of ten (10) investors (collectively, the “Lenders”), including JEQ Capital AB, the Company’s largest current shareholder. None of the Lenders are considered related parties to the Company under applicable regulations, and

DanCann Pharma A/S signs a conditional sales agreement for the sale of manufacturing site (BP1), secures bridge financing, and launches new strategy, Maturity2028

COPENHAGEN, Denmark, 9 July 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces that the Company has received a conditional sales agreement regarding the sale of its production facility, Biotech Pharm1 (“BP1”), at a total consideration of EUR 1.25 million (DKK 9.32 million). In continuation of this, the Company has secured bridge financing for DKK 2 million to bridge liquidity until final sale of BP1, and to help propel its new Maturity2028 strategy.Conditional sales agreement for BP1 Since the Company’s

DanCann Pharma A/S: Delivers Q1-2025 Highlights – Expands Prescription (Rx) Portfolio, Eyes Consumer Health Market Entry (OTC)

COPENHAGEN, Denmark, 23 May 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the first quarter (Q1) of 2025. The Q1-2025 report is available as an attached document to this press release and at www.dancann.com.Summary: Group Key Figures Q1-2025   +-------------+----------+-------------------+----------------+----------------+|DKK 1,000 |01/01/25 |01/01/24 – 31/03/24|2024 (Full year)|2023 (Full year)|| |– 31/03/25| |

DanCann Pharma A/S: Præsenterer højdepunkter fra 1. kvartal 2025 – Udvider receptportefølje (Rx) og forbereder indtræden på markedet for håndkøbsprodukter (OTC)

København, Danmark, 23. maj 2025 – DanCann Pharma A/S (Spotlight: DANCAN) (“DanCann Pharma” eller “Selskabet”), et dansk biofarmaceutisk selskab med fokus på cannabinoider, meddeler hermed, at Selskabet har offentliggjort sin rapport for første kvartal (Q1) 2025. Rapporten er vedhæftet denne meddelelse og er tilgængelig på Selskabets hjemmeside: www.dancann.com.Hovedtal for Selskabet – 1. kvartal 2025 (i DKK 1.000)   +---------------+-------------------+-------------------+---------+---------+|Periode |01.01.25 – 31.03.25|01.01.24 – 31.03.24|Hele 2024|Hele 2023|+------------

DanCann Pharma A/S: Receives Regulatory Approval for Bedrolite® and Bedrobinol® from the Danish Medicines Agency under the Danish Pilot Programme

COPENHAGEN, Denmark, 19 May 2025 – DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”), a Danish company powered by cannabinoids, hereby announces that the Company has obtained approval from the Danish Medicines Agency for the distribution of Bedrolite® and Bedrobinol® under the Danish Pilot Programme for medicinal cannabis, through its wholly owned subsidiary CannGros ApS. The approval of these new products is in line with the Company’s communicated guidance and is expected to have a positive impact on sales performance going forward.DanCann Pharma has received confirmation

DanCann Pharma A/S: Adoption of Permanent Medicinal Cannabis Legislation in Denmark Completed

COPENHAGEN, Denmark, 25 April 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces the recent adoption of Bill L135 by the Danish Parliament, which establishes a permanent legislative framework for the current medicinal cannabis Pilot Programme and formalizes the regulatory environment for medical use of cannabis in Denmark.This legislative milestone confirms Denmark’s commitment to a long-term, structured integration of cannabinoid-based medicines into the national healthcare system. Bill L135 was adopted

DanCann Pharma A/S: Updated Financial Calendar for the Remainder of 2025

COPENHAGEN, Denmark, 24 April 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces an update to its financial calendar for the remainder of the fiscal year 2025. The updated financial calendar is also available on the Company’s website at www.dancann.com.Updated Financial Calendar for 2025:   Annual Report 2024: April 04, 2025 (PM 06:00 CET)   Annual General Meeting: April 24, 2025 (AM 09:00 CET)   Q1 2025 Report: May 23, 2025 (PM 06:00 CET)   Q2 2025 Report: August 25, 2025 (PM 06:00

DANCANN PHARMA A/S: MINUTES OF ANNUAL GENERAL MEETING

held in DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”)Thursday, 24 April 2025 at 09:00 am (CET) On 24 April 2025 at 09:00 am (CET), the annual general meeting of 2025 was held in the Company at the Company’s address, Rugvænget 5, 6823 Ansager, Denmark. The agenda for the annual general meeting was as follows: `. 1. 1. 1. 1. 1. 1. The chairman’s report on the activities of the Company in the past financial year 2. Adoption of the annual report for 2024 3. Covering of loss pursuant to the adopted

DanCann Pharma A/S: Notice of Annual General Meeting in DanCann Pharma A/S

The Board of Directors hereby convenes the annual general meeting 2025 of DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”), to be held on Thursday, 24 April 2025 at 09:00 am (CET) at DanCann Pharma A/S’ address, Rugvænget 5, 6823 Ansager, Denmark The agenda for the annual general meeting is as follows: The chairman’s report on the activities of the Company in the past 1. financial year  Adoption of the annual report for 2024 2.  Covering of loss pursuant to the adopted annual report for 2024 3.  Election of members of the Board of Directors

DanCann Pharma A/S Releases 2024 Annual Report Highlighting Growth and Operational Efficiency

APRIL 2025 Copenhagen, Denmark, April 4, 2025 — DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”), a leading Danish biopharmaceutical company specialized in cannabinoid-based therapies, hereby announces that the Board of Directors and the Chief Executive Officer have today approved and published the Annual Report for the financial year 2024. The report is now available on the Company’s website and via this press release.Financial Highlights for 2024: · Revenue amounted to DKK 7.37 million, reflecting a year-over-year increase of 21.4% (2023: DKK 6.07 million).

DanCann Pharma A/S: Postponement of release of annual report 2024 and AGM 2025

COPENHAGEN, Denmark, 27 March 2025 DanCann Pharma A/S’ annual report 2024 was planned to be released on 31 March 2025, and the annual general meeting 2025 was planned to be held on 14 April 2025. The release of the annual report 2024, the notice of the annual general meeting 2025 and the holding of the annual general meeting 2025 are postponed to the following dates: Release of annual report 2024 4 April 2025Notice of annual general meeting 2025 4 April 2025Annual general meeting 2025 24 April 2025 DanCann Pharma A/S’ financial calendar has been updated

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media

Rss